Category Archives: R&D

Risking It All? Risk-Based Monitoring at Cancer Research UK

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches […]
Also posted in Strategy | Tagged , , , , | Leave a comment

Tufts Figures on Drug Development Spark Debate

By Agnes Shanley, Pharmaceutical Technology. The Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug. Although the study acknowledges that it still takes about 10 years to launch a new brand-name pharmaceutical, this year, the costs required were estimated at $2.6 […]
Also posted in Strategy | Tagged , , | 1 Comment

Tufts Pegs Drug Development Cost at $2.6 billion – MSF Cries Foul

A cool $2.6 billion is the going rate to develop and gain market approval for a drug, according to the recent study by the Tufts Center for the Study of Drug Development (CSDD).
Posted in R&D | Tagged , , | Leave a comment

Do Oncology Trials Need PR?

Only 3% to 5% of cancer patients participate in clinical trials. Although oncology projects account for almost 31% of global projects, it remains the most difficult therapeutic area in which to conduct clinical trials.  Why, and what can be done to improve patient recruitment?
Posted in R&D | Tagged , | Leave a comment

Top 10 Medical Innovations for 2015

The Cleveland Clinic once again ended its Medical Innovation Summit with a list of 10 advances voted most likely to have a major impact on improving patient care in 2015.
Also posted in Events | Tagged , | Leave a comment
  • Categories

  • Meta